Callitas Health Inc.

Callitas Health working with British Columbia Securities Commission to lift cease-trade order

The passing of Callitas’ former CEO delayed the filing of its second-quarter financial statements

Stack of paper on a desk
Callitas develops over-the-counter consumer goods, including wellness products and cannabis technologies

Callitas Health Inc (CSE: LILY, OTCQB: MPHMF) is working with Canadian regulators to lift a cease-trading order after missing a recent filing deadline.

The clinical-stage pharmaceutical company delayed filing its second-quarter financial statements with the British Columbia Securities Commission amid a series of family issues, including the recent passing of former CEO Gary Thompson.

Callitas Health, as a result, received a cease-trade order from the Commission.

BIG PICTURE: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

"The Callitas management team has every intention of meeting this filing obligation," said CEO James Thompson in a company press release. "The management team has been finalizing our corporate reporting documents and expect to fulfill the Commission's requirements.”

Callitas has until September 30 to submit the necessary documents in order for the halt to be lifted.

The company develops over-the-counter consumer goods, including female sexual health and wellness products and cannabis delivery technologies.

Shares of Callitas fell nearly 22% to US$0.10 by Monday’s close.

Quick facts: Callitas Health Inc.

Price: $0.11

Market: CSE
Market Cap: $3.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc. named herein, including the promotion by the Company of Callitas Health Inc. in any Content on the Site, the Company...



Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 04/25/2019

2 min read